Article Text

other Versions

PDF
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers
  1. Ashish B Rajput (ashish.rajput{at}vch.ca)
  1. Genetic Pathology Evaluation Centre, Canada
    1. Melinda A Miller (memiller{at}bccancer.bc.ca)
    1. 3Center for Translational and Applied Genomics, Canada
      1. Alessandro De Luca (alessandro.deluca{at}vch.ca)
      1. 3Center for Translational and Applied Genomics, Canada
        1. Niki Boyd (boyd.niki{at}gmail.com)
        1. Translational and Applied Genomics, Canada
          1. Sam Leung (sam.leung{at}vch.ca)
          1. Genetic Pathology Evaluation Centre, Canada
            1. Antonio Hurtado-Coll (antonio.hurtadocoll{at}vch.ca)
            1. The Prostate Centre at Vancouver General Hospital, Canada
              1. Ladan Fazli (ladan.fazli{at}vch.ca)
              1. The Prostate Centre at Vancouver General Hospital, Canada
                1. Edward C Jones (edward.jones{at}vch.ca)
                1. Vancouver General Hospital, Canada
                  1. Jodie B Palmer (jodie.palmer{at}vch.ca)
                  1. The Prostate Centre at Vancouver General Hospital, Canada
                    1. Martin E Gleave (gleave{at}interchange.ubc.ca)
                    1. The Prostate Centre at Vancouver General Hospital, Canada
                      1. Michael E Cox (michael.cox{at}vch.ca)
                      1. The Prostate Centre at Vancouver General Hospital, Canada
                        1. David G Huntsman (dhuntsma{at}bccancer.bc.ca)
                        1. Genetic Pathology Evaluation Centre and British Columbia Cancer Agency, Canada

                          Abstract

                          Background: Recent reports indicate that prostate cancers (CaP) frequently over-express the potential oncogenes, ERG or ETV1. Many cases have chromosomal rearrangements leading to the fusion of the 5’ end of the androgen-regulated serine protease TMPRSS2 (21q22.2) to the 3’ end of either ERG (21q22.3) or ETV1 (7p21.3). The consequence of these rearrangements is aberrant androgen receptor-driven expression of the potential oncogenes, ETV1 or ERG.

                          Aim: To determine the frequency of rearrangements involving TMPRSS2, ERG, or ETV1 genes in CaP of varying Gleason grades through fluorescent in situ hybridization (FISH) on CaP tissue microarrays (TMAs).

                          Methods: Two independent assays, a TMPRSS2 break-apart assay and a three-colour gene fusion FISH assay were applied to TMAs. FISH positive cases were confirmed by reverse transcriptase - polymerase chain reaction (RT-PCR) and DNA sequence analysis.

                          Results: 106/196 (54.1%) cases were analyzed by FISH. None of the five benign prostatic hyperplasia cases analyzed exhibited these gene rearrangements. TMPRSS2:ERG fusion was found more frequently in moderate to poorly differentiated tumours (35/86, 40.7%) than in well-differentiated tumours (1/15, 6.7%, p = 0.017). TMPRSS2:ETV1 gene rearrangement was not detected in all of the cases tested. TMPRSS2:ERG fusion product was verified by RT-PCR followed by DNAsequencing in 7/7 randomly selected positive cases analysed.

                          Conclusion: This study indicates that TMPRSS2:ERG gene rearrangements in CaP may be used as a diagnostic tool to identify prognostically relevant sub-classifications of these cancers.

                          • FISH
                          • Gene fusion
                          • Prostate cancer
                          • TMPRSS2:ERG

                          Statistics from Altmetric.com

                          Request permissions

                          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                          Linked Articles